The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > REGULATORY
REGULATORY
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
- 51 Products Officially Filed for Sakigake Designation after MHLW Screening
September 18, 2015
- Add Myasthenia Gravis, Myositis to Opdivo Label: MHLW
September 17, 2015
- Toxic Epidermal Necrolysis Added to Clinically Significant ADR List for Vectibix
September 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 24 - September 13
September 15, 2015
- Japan to Help Fight Infectious Diseases in Developing Nations: Basic Policy
September 15, 2015
- Bevacizumab, 2 Other Compounds Designated as Orphan Drugs
September 15, 2015
- Kaketsuken Reports Results of Internal Probe on Improper Blood Product Manufacturing
September 11, 2015
- 1 Million Signatures Collected Opposing Exclusion of Kampo from Reimbursement; “Discussion Closed”: LDP Kampo Supporters
September 11, 2015
- MHLW Reports on “Comprehensive Strategy” at Chuikyo
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- MHLW Launches Office to Promote Genomic Medicine
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
- Research-Driven Makers Need Enough Capital Strength to Withstand Discontinuation of R&D Projects: Comprehensive Strategy
September 8, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- Notification Service for Generic Use Saves 15.8 Billion Yen in Medical Spending in FY2014: Kyokai Kenpo
September 8, 2015
- MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation
September 7, 2015
- Japan Medical Spending Hits Another Record in FY2014, Year-End Generic Share at 58.4%: MHLW
September 7, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…